Artificial intelligence and its expanding role across the biopharma landscape

Artificial intelligence (AI) has become a widely used tool in the biopharma industry, particularly in research and development. However, there is still room for increased integration of AI in downstream commercial operations, as an example. Biopharma organizations are exploring the use of generative AI, such as OpenAI’s ChatGPT, to enhance the drug discovery process and augment operations.

This paper, Artificial intelligence and its expanding role across the biopharma landscape, outlines key trends in the industry, including the top 10 biopharmas’ investment strategies and the adoption of AI. It also evaluates the expanding landscape of AI-focused entities in the pharmaceutical space.

As biopharma organizations evolve on the journey of AI adoption, some things to keep in mind include: align with AI-focused biotech companies, build integrated AI systems, co-create solutions with ecosystem partners, plan for incremental AI adoption, enhance change management, and consider the broader technology stack.

This is an exciting time in the industry as AI-driven biopharma companies will continue to grow and play a pivotal role by enhancing existing capabilities and bolstering pipeline activities.